Group 1 - The pharmaceutical sector is experiencing a strong rebound, with the Kexin Innovation Drug ETF (589720) rising nearly 5% and seeing continuous net inflows for three consecutive days [1] - The World Lung Cancer Conference (WCLC) and the European Society for Medical Oncology (ESMO) will showcase research results of domestic innovative drugs, including AK112 from Kangfang Biotech and DB-1311 from Ying'en Biotech, in September and October 2025 [1] - The competitiveness of domestic innovative drugs in clinical data and progress is increasing globally, leading to a trend of innovative drugs expanding into international markets [1] Group 2 - The Kexin Innovation Drug ETF (589720) focuses on innovative drug companies listed on the Sci-Tech Innovation Board, tracking a representative index of 30 high-quality companies, primarily in the biotech sector [1] - Since the "924 market" rally, the Kexin Innovation Drug Index has outperformed major Hong Kong innovative drug indices, with respective gains of 75%, 70%, and 70% during the market rebound period from September 24, 2024, to June 30, 2025 [1] - The Kexin Innovation Drug Index may provide better exposure to the resilience of the Sci-Tech Innovation Board when market risk appetite increases [1]
科创创新药ETF(589720)涨近5%,指数跑赢主要港股创新药指数
Mei Ri Jing Ji Xin Wen·2025-08-29 11:20